Bavarian Nordic A/SDanish vaccine maker Bavarian Nordic A/S has submitted data to the EMA that support label extension of its mpox vaccine imvanex indication to include adolescents 12 to 17 years of age.
After the drug discovery specialist Evotec SE lowered its annual forecast and lost almost 75% of its market capitalisation in just eight months, the new CEO, Christian Wojczewski, is taking action and closing non-profitable areas.
Max Planck Institute for Terrestrial Microbiology/GeiselInvestigating substrate selectivity of nitrogenase enzymes in phototrophic R. capsulatus bacteria, German microbiologist have found one converting CO2 to formiate and methane opening the way to fossil oil-free hydrocarbon synthesis
Sphingotec GmbHGerman diagnostics specialist SphingoTec GmbH has closed a €5m Series C financing round led by Think.Health Ventures.
A Dutch-German resarch team together with Evotec SE have presented a new class of vancomycin derivatives with good safety profile that kill multi-resistant, Gram-positive bugs.
Sangamo Therapeutics IncAfter Sangamo Therapeutics Inc. presented an epigenetic ZFN-based repressor at ASGCT 2024 that reduces the expression of the tau protein in the hippocampus by 95% in Alzheimer’s models, Roche’s US subsidiary Genentech has licensed the experimental gene therapy.
Carbios SASFrench bioplastics recycling specialist Carbios SAS and British recycling and waste management company FCC Environment want to establish a PET biorecycling facility in the UK.
Adaütimmune LtdThe US Food & Drug Administration has granted accelerated approval to Adaptimmune’s Tecelra as the world’s first therapy with genetically engineered T cells to fight a solid tumour.
Armed Forces Institute of Pathology, AFIPFrench-Austrian vaccine maker Valneva SE has secured exclusive worldwide rights to commercialise LimmaTech Biologics AG’s S4V Shigella vaccine that will be tested in two Phase II trials starting in H2/2024.
SIATWith an investment of its venture arm (BI-VF), Boehringer Ingelheim underlines its committment to expand the reach of cancer immune therapies. The Series A financing in Chinese Synthetica Pioneering that engineers oncolytic bacteria to deliver toxic payloads or modulators of the tumour environment to solid tumours follows an investment in T3 Pharmaceuticals.